Discover how the latest population-based analysis reveals comparable long-term outcomes between two frontline therapies for Waldenström macroglobulinemia, shedding light on treatment decisions in the real-world setting.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Kim et al., Leuk Lymphoma 2023
DOI: 10.1080/10428194.2023.2290466
Oh, brace yourselves for the latest groundbreaking revelation in the world of Waldenström macroglobulinemia (WM) treatment! We’ve got a whopping sample of 111 patients who’ve never had the pleasure of treatment before, and they were split between the trendy bendamustine-rituximab (BR) cocktail and the retro rituximab-cyclophosphamide-vincristine-prednisone (RCVP) mix.
Now, get this: after a median follow-up of 60.7 months, which is just enough time to binge-watch every medical drama out there, the progression-free survival (PFS) was 60.5 months for the BR fans and a slightly more impressive 79.0 months for the RCVP group. But hold your applause, because the difference was statistically insignificant (p = .96). That’s right, the suspense was for nothing!
As for the overall survival (OS), BR patients are still hanging in there with no median reached, while RCVP patients clocked in at a median of 153.4 months. Again, no statistical confetti to throw around (p = .37).
But wait, there’s a twist! BR had a few more patients achieving the very good partial response or even better (51% vs. 37%, p = .30) and complete response (26% vs. 13%, p = .13). However, these numbers are like a cliffhanger at the end of a season – suggestive, but not conclusive.
In the end, RCVP is like that reliable old friend who’s just as good as the new kid on the block, especially when you’re a bit frail or counting your pennies. So, for those living in the real world with TN WM, it’s good to know that you’ve got options. And isn’t that what life’s all about? Choices, dear patients, choices.